BREMELANOTIDE CLINICAL TRIAL RESULTS TO BE PRESENTED AT MEETING

King Pharmaceuticals and Palatin Technologies have announced today that a scientific presentation will be given at the upcoming International Society for the Study of Women's Sexual Health annual meeting in Lisbon, Portugal.

The will cover emerging therapies for the treatment of female sexual dysfunction (FSD) and the previously disclosed data from a clinical trial evaluating the effects of bremelanotide on pre-menopausal women diagnosed with FSD.

Bremelanotide is the first compound in a new drug class called melanocortin receptor agonists under development to treat sexual dysfunction. This new chemical entity is being evaluated in Phase II clinical trials studying the efficacy and safety profile of varying doses of this novel compound in men experiencing erectile dysfunction and women experiencing FSD.